Jury Still Out On Beta Amyloid Target In Early Alzheimer’s
This article was originally published in The Pink Sheet Daily
Executive Summary
New data analyses at the Alzheimer’s Association International Congress spur some optimism, but analysts advise caution about whether they will actually translate into clinically meaningful benefits in pivotal trials.